Our Founders

Annexon was established in 2011 based on discoveries by co-founder, Dr. Ben Barres, Former Chair of Neurobiology, Stanford University, that revealed the role of the classical complement pathway in synaptic elimination within the central nervous system. With co-founder Dr. Arnon Rosenthal, a world-renowned scientist and industry executive, Annexon was created to pursue game-changing therapies that halt the progression of complement-mediated disease processes for the treatment of autoimmune and neurodegenerative disorders.

Arnon Rosenthal PhD

CO-FOUNDER & CEO
ALECTOR

Ben Barres MD, PhD

FORMER CHAIR OF NEUROBIOLOGY
STANFORD UNIVERSITY
Leadership Board of Directors Scientific Advisors Investors